

Alexandra Degenhardt, Sreeram V. Ramagopalan, Antonio Scalfari and George C. Ebers

Clinical prognostic factors in multiple sclerosis: a natural history review

Nature Reviews Neurology 5, 672-682 (December 2009)

A.Scalfari, A.Neuhaus, A.Degenhardt, G.P.Rice, P.A Muraro, M.Daumer and G.C.Ebers

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability.

Brain 2010 133: 1914-1929

A.Scalfari, R. Nicholas, O. Malik and PA Muraro

Escalating Immunotherapies for highly active multiple sclerosis: reviewing the evidence.

CML-Multiple Sclerosis 2010; 2(3):61-73

Ebers GC, Daumer M, Scalfari A

Predicting a therapeutic opportunity in multiple sclerosis

Brain 2010; 133 (Pt 12): e162

Ebers GC, Daumer M, Scalfari A

Surrogate endpoints for EDSS worsening in multiple sclerosis: a meta-analytic approach: measuring disability in relapsing-remitting MS.

Neurology 2011;76 (11): 1025

A. Scalfari, A. Neuhaus, M. Daumer, G.C. Ebers, and P. A. Muraro

Age and disability accumulation in multiple sclerosis

Neurology 2011. 27;77 (13): 1246-52

Ebers GC, Scalfari A, Daumer M, Lederer C.

Combined MRI lesions and relapses as surrogate for disability in MS

Neurology 2012;78 (17): 1367

A.Scalfari, A. Neuhaus, M. Daumer, GC DeLuca, P. A. Muraro G.C. Ebers,

Early relapses, onset of progression and late outcomes in multiple sclerosis

JAMA Neurology 2013 Feb; 70(2):214-22

I. Galea, C. Lederer, A. Neuhaus, P. A. Muraro, A. Scalfari, N. Koch-Henriksen, C. Heesen, S. Koepke, P. Stellmann, H. Albrecht, A. Winkelmann, F. Weber, E. Bahn, M. Hauser, G. Edan, G. Ebers and M. Daumer

A Web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis

European Journal of Neurology 2013 Jul; 20(7):1107-9

A.Scalfari, A. Knapperts V, Cutter G, Goodin DS, Ashton R and G.C. Ebers,

Mortality in patients with multiple sclerosis

Neurology 2013 Jul 9; 81 (2): 184-92

A.Scalfari, A. Neuhaus, M. Daumer, P. A. Muraro G.C. Ebers,

Onset of secondary progressive phase and long term evolution of multiple sclerosis

JNNP 2014 Jan;85(1):67-75.

A. Scalfari

Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome – NO

Multiple Sclerosis Journal 2015, Vol 21 (11), 1371-1375

M. Calabrese, R. Reynolds, R. Magliozzi, M. Castellaro, A. Morra, A. Scalfari, G. Farina, C. Romualdi, A. Gajofatto, M/ Pitteri, MD. Benedetti, S. Monaco

Regional distribution and evolution of gray matter damage in different population of multiple Sclerosis patients.

PLoS One 2015 Aug 12.

A. Scalfari, C. Lederer, M. Daumer, R. Nicholas, GC. Ebers, PA. Muraro

The relationship of age with the clinical phenotype in multiple sclerosis

Multiple Sclerosis Journal, 2016 Nov; 22(13): 1750-1758

Nandoskar A, Raffael J, Scalfari A, Friede T, Nicholas R

Pharmacological approaches to the management of secondary progressive multiple sclerosis

Drugs. 2017 May; 77(8):885-910

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Cochrane Database Syst Rev. 2017 Apr 25;4